79839-26-2

Usage

Chemical Properties

White to yellow solid

InChI:InChI=1/C11H18N2O5/c1-11(2,3)18-10(17)12-7-4-5-13(9(7)16)6-8(14)15/h7H,4-6H2,1-3H3,(H,12,17)(H,14,15)/t7-/m0/s1

Upstream product

• 114200-38-3 methyl (3S)-3-((S)-1-t-butyloxycarbonylamino)-2-oxopyrrolidinoacetate 
• 79839-23-9 Boc-Met-Gly methyl ester methylsulfonium iodide 

Downstream Products

• 114200-40-7 3(S)-<amino>-2-oxo-1-pyrrolidineacetamide 
• 106732-52-9 3(S)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide 
• 174960-87-3 C₁₉H₂₉N₇O₇S 
• 174960-88-4 N-((S)-4-Guanidino-1-hydroxymethyl-butyl)-2-((S)-2-oxo-3-phenylmethanesulfonylamino-pyrrolidin-1-yl)-acetamide 

Relevant academic research and scientific papers

3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS

The present invention discloses peptide aldehydes having a lactam group as part of the peptide backbone and having an original mimic group such as an amidinopiperidine or amidinophengyl tail. These compounds are potent and specific inhibitors of thrombin,

Inhibition of human neutrophil elastase. 4. Design, synthesis, X-ray crystallographic analysis, and structure-activity relationships for a series of P2-modified, orally active peptidyl pentafluoroethyl ketones

A series of P2-modified, orally active peptidic inhibitors of human neutrophil elastase (HNE) are reported. These pentafluoroethyl ketone-based inhibitors were designed using pentafluoroethyl ketone 1 as a model. Rational structural modifications were made at the P3, P2, and activating group (A(G)) portions of 1 based on structure-activity relationships (SAR) developed from in vitro (measured K(i)) data and information provided by modeling studies that docked inhibitor 1 into the active site of HNE. The modeling-based design was corroborated with X-ray crystallographic analysis of the complex between 1 and porcine pancreatic elastase (PPE) and subsequently the complex between 1 and HNE.

3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease

Dopamine Receptor Modulation by Conformationally Constrained Analogues of Pro-Leu-Gly-NH2

Two series of conformationally constrained analogues of Pro-Leu-Gly-NH2 (PLG) have been synthesized.In one series of analogues, the Leu-Gly-NH2 dipeptide segment of PLG was replaced with the γ-lactam residues 3(S)- and 3(R)-amino-2-oxopyrrolidineacetamide

Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides

General methods have been devised for the synthesis of lactam-constrained dipeptide analogues having five-, six-, and seven-membered rings.Three different paths from protected chiral α-amino acids to lactams involving intramolecular alkylation, intramolecular acylation, and insertion of a one carbon unit by condensation with formaldehyde have been utilized.The first two methods produce chiral products stereospecifically, but considerable racemization occurs in the third route which leads to a 4-oxo-5-amino-1,3-thiazine (13).The products are prepared in good yield and have protecting groups making them suitable for incorporation into higher peptides by methods commonly used.